Monitor for any subsequent equity offering announcement (e.g., S-1 or prospectus) now that the share authorization is being sought, the company explicitly states it needs capital to fund clinical trials. The November 3 meeting outcome is likely favorable given the lowered vote threshold and broker discretion.
Price Chart
Executive Summary
Annovis Bio filed a DEFA14A supplement to its proxy statement, postponing the special meeting from October 14 to November 3, 2026, and amending Proposal 1 to seek approval only for increasing authorized common shares from 70M to 140M (removing the preferred stock increase). The vote standard for Proposal 1 changed from a majority of outstanding shares to a majority of votes cast due to an August 2026 Delaware law amendment, and brokers now have discretionary authority on this routine matter. This is a procedural cleanup that removes a potential voting complication but signals the company's need for additional equity to fund clinical trials.
Key Financial Metrics
Key Facts
- Special meeting postponed from October 14, 2026 to November 3, 2026.
- Proposal 1 amended to only increase authorized common shares from 70M to 140M (preferred stock increase removed).
- Vote standard for Proposal 1 changed to majority of votes cast (from majority outstanding) due to August 2026 DGCL amendment.
- Brokers now have discretionary authority to vote on Proposal 1.
- Record date remains September 4, 2026; previously submitted proxies remain valid.
- Proxies previously submitted on Proposal 1 will be voted as indicated on the amended proposal.
Financial Impact
No direct financial impact; the amendment enables future equity issuance of up to 70M additional common shares, but no specific offering is announced.
Risk Factors
- Potential dilution risk if the authorized shares are used for a dilutive offering.
- No guarantee the share increase will pass despite favorable vote standard.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-114231 |
| Document: 0001104659-26-114231-index-headers.html | 0001104659-26-114231 |
| Document: 0001104659-26-114231-index.html | 0001104659-26-114231 |
| Document: 0001104659-26-114231.txt | 0001104659-26-114231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 9d ago | 8-K | $0.9783 | awaiting T+60 | awaiting T+60 | $1.01 (+3.75%) |
Oct 15, 2026 14d ago | SC 13G/A | $1.05 | awaiting T+60 | awaiting T+60 | $1.01 (−3.33%) |
Oct 7, 2026 22d ago | DEFA14A | $1.21 | awaiting T+60 | awaiting T+60 | $1.01 (−16.12%) |
Jul 9, 2026 15w ago | 8-K | $1.86 $1.20 | ▼ −35.48% | ▼ −38.12% | $1.01 (−45.43%) |
May 20, 2026 23w ago | 424B5 | $2.15 $1.74 | ▲ +19.07% | ▲ +23.37% | $1.01 (+52.79%) |
May 19, 2026 23w ago | 424B5 | $2.04 $1.85 | ▲ +9.31% | ▲ +14.32% | $1.01 (+50.25%) |
May 15, 2026 23w ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
May 15, 2026 23w ago | Press Release | $2.06 $1.89 | ▲ +8.25% | ▲ +12.77% | $1.01 (+50.73%) |
Apr 10, 2026 28w ago | Press Release | $1.59 $1.92 | ▲ +20.75% | ▲ +10.43% | $1.01 (−36.16%) |
Mar 19, 2026 32w ago | Press Release | $2.67 $1.78 | ▼ −33.33% | ▼ −47.68% | $1.01 (−61.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers